CGTX – cognition therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes [Yahoo! Finance]
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 [Yahoo! Finance]
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Form 424B5 COGNITION THERAPEUTICS
Form S-8 COGNITION THERAPEUTICS
Form 10-K COGNITION THERAPEUTICS For: Dec 31
Form 8-K COGNITION THERAPEUTICS For: Mar 20
Form 8-K COGNITION THERAPEUTICS For: Mar 12
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.